HBVZ10 exhibits robust in vivo potency and synergizes with entecavir to drive efficient cccDNA elimination and HBsAg seroclearance

Simple item page
dc.contributor.authorZhang Bai-Hua
dc.contributor.authorZhou Yuanping
dc.contributor.authorWu Yukun
dc.contributor.authorHorrigan Stephen
dc.contributor.authorLuckenbaugh Laura
dc.contributor.authorHu Jianming
dc.contributor.authorZoulim Fabien
dc.contributor.authorZhang Yong-Yuan
dc.date.accessioned2026-09-23T13:45:42Z
dc.date.issued2026-10
dc.identifier.doi10.1016/j.antiviral.2026.106518
dc.identifier.urihttps://pubs.cidrz.org/handle/123456789/13732
dc.identifier.uri.pubmedhttps://doi.org/10.1016/j.antiviral.2026.106518
dc.sourceAntiviral Research
dc.titleHBVZ10 exhibits robust in vivo potency and synergizes with entecavir to drive efficient cccDNA elimination and HBsAg seroclearance

Files

Collections

Published